Phase 2 Study of ADX-038 Targets Complement-Mediated Kidney Disease
A Phase 2 study is underway to evaluate ADX-038 for safety and efficacy in adults with complement-mediated kidney diseases.
Asset / Drug
Drug and asset intelligence for ADX-038 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.